Treatment progress of pulmonary hypertension associated with bronchopulmonary dysplasia in preterm infants
10.3760/cma.j.issn.1673-4408.2023.03.003
- VernacularTitle:早产儿支气管肺发育不良相关肺动脉高压治疗进展
- Author:
Ruobing LIANG
1
;
Qiaomian ZHU
;
Jianping LIU
;
Huiping ZHANG
Author Information
1. 西安交通大学附属儿童医院新生儿重症医学科 710082
- Keywords:
Pulmonary arterial hypertension;
Bronchopulmonary dysplasia;
Preterm infants;
Treatment
- From:
International Journal of Pediatrics
2023;50(3):154-158
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension(PH)is commonly seen in preterm infants with bronchopulmonary dysplasia(BPD)and is significantly associated with increased mortality.The pathophysiological basis of PH is pulmonary vascular dysplasia or remodeling, and airways hyperresponsiveness.At present, management of BPD-PH should be comprehensive supportive therapy and focus on targeted pharmacotherapies, including various pulmonary vasodilators with different vasoactive mechanisms, such as phosphodiesterase inhibitors, endothelin receptor antagonists and prostaglandins analogs.However, although expert consensus recommends targeted pulmonary arterial hypertension therapy, high-quality clinical studies on the safety and efficacy of these drugs are few.Pulmonary vascular remodeling inhibitors and stem cell therapy have enormous potential to reduce pulmonary hypertension and further research and more data are needed.
